Metformin and -cell function in insulin-treated patients with type 2 diabetes: A randomized placebo-controlled 4.3-year trial

Wiebe Top, Coen Stehouwer, Philippe Lehert, Adriaan Kooy*

*Corresponding author for this work

    Research output: Contribution to journalArticleAcademicpeer-review

    5 Citations (Scopus)
    361 Downloads (Pure)

    Abstract

    In this trial, 390 insulin-treated patients with type 2 diabetes were randomized to either placebo or metformin. Fasting levels of glucose, insulin and C peptide were determined at baseline, after 4 months and yearly thereafter for 4 years to assess fasting estimates of beta cell function. The primary endpoint was the fasting C peptide-to-glucose ratio (FCPGR) and secondary measures were the disposition index (DI) and the fasting C peptide (FCP). We analysed the results with a general linear mixed model. Baseline FCPGR was 5.27 (95% CI, 4.83 - 5.71). Compared to placebo, FCPGR increased in the metformin group with 1.48 (95% CI, 1.09 - 1.87, P

    Original languageEnglish
    Pages (from-to)730-733
    Number of pages4
    JournalDiabetes obesity & metabolism
    Volume20
    Issue number3
    DOIs
    Publication statusPublished - Mar-2018

    Keywords

    • beta cell function
    • HOME study
    • metformin
    • RCT
    • type 2 diabetes
    • GLUCOSE-TOLERANCE
    • PANCREATIC-ISLETS
    • C-PEPTIDE
    • SECRETION
    • BETA
    • SENSITIVITY

    Cite this